SCHEMBL17758799

SCHEMBL17758799

Clc1ncc(Cc2cccc(-n3cccn3)c2)s1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.46
MPO P05164 1/20 0.45
GLS O94925 2/20 0.42
PI4KB Q9UBF8 1/20 0.42
NOTUM Q6P988 1/20 0.41
ALDH1A1 P00352 1/20 0.40
MAPT P10636 2/20 0.39
KLKB1 P03952 1/20 0.38
KLK1 P06870 1/20 0.38
HCRTR1 O43613 2/20 0.38
HCRTR2 O43614 2/20 0.38
KMT2A Q03164 3/20 0.38
RECQL P46063 1/20 0.38
MEN1 O00255 1/20 0.37
OPRK1 P41145 1/20 0.37
CCR6 P51684 1/20 0.37
MCOLN3 Q8TDD5 1/20 0.37
ERCC1 P07992 1/20 0.37
ERCC4 Q92889 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17758747 0.85 NOTUM (0.51) LMNAMPONOTUMALDH1A1MAPT
SCHEMBL20929496 0.85 NOTUM (0.38) LMNAMPOGLSPI4KBNOTUM
SCHEMBL17758820 0.80 LMNA (0.46) LMNAMPOGLSPI4KBALDH1A1
SCHEMBL20929259 0.80 POLB (0.35) LMNAPI4KBNOTUMALDH1A1MAPT
SCHEMBL17758811 0.79 SMN1; SMN2 (0.49) LMNAMPOGLSALDH1A1MAPT
SCHEMBL23352194 0.78 LMNA (0.44) LMNANOTUMALDH1A1MAPTKLKB1
SCHEMBL17758803 0.77 MAPT (0.41) LMNAMPOGLSPI4KBALDH1A1
SCHEMBL20929575 0.76 HCRTR1 (0.40) ALDH1A1MAPTHCRTR1HCRTR2KMT2A
SCHEMBL23352235 0.76 MAPT (0.38) ALDH1A1MAPTHCRTR1HCRTR2KMT2A
SCHEMBL17758815 0.76 LMNA (0.44) LMNAMPOGLSMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11459321-B2 Broad spectrum antiviral compositions and methods EVRYS BIO, LLC (US) 2022-10-04 US disclosed
US-11358961-B2 Anti-HCMV compositions and methods EVRYS BIO, LLC (US) 2022-06-14 US disclosed
US-20220135556-A1 ANTI-HCMV COMPOSITIONS AND METHODS EVRYS BIO, LLC (US) 2022-05-05 US disclosed
US-20210139475-A1 Broad Spectrum Antiviral Compositions and Methods EVRYS BIO, LLC (US) 2021-05-13 US disclosed
EP-3218373-B1 ANTI-HCMV COMPOSITIONS AND METHODS EVRYS BIO LLC (US) 2020-07-22 EP disclosed
US-20200140429-A1 ANTI-HCMV COMPOSITIONS AND METHODS EVRYS BIO, LLC (US) 2020-05-07 US disclosed
US-10556894-B2 Anti-HCMV compositions and methods EVRYS BIO, LLC (US) 2020-02-11 US disclosed
WO-2019079519-A1 BROAD SPECTRUM ANTIVIRAL COMPOSITIONS AND METHODS FORGE LIFE SCIENCE, LLC (US) 2019-04-25 WO disclosed
WO-2016077232-A2 ANTI-HCMV COMPOSITIONS AND METHODS FORGE LIFE SCIENCE, LLC (US) 2016-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11459321-B2 Broad spectrum antiviral compositions and methods IRF3, MAVS, ZC3HAV1 LMNA 2718/4885MPO 3412/4885GLS 1655/4885
US-11358961-B2 Anti-HCMV compositions and methods RPL35, RPL7, RPL5 LMNA 1720/4885MPO 2075/4885GLS 2041/4885
US-10556894-B2 Anti-HCMV compositions and methods RPL35, RPL7, RPL5 LMNA 1720/4885MPO 2075/4885GLS 2041/4885
US-20210139475-A1 Broad Spectrum Antiviral Compositions and Methods MAVS, IRF3, ZC3HAV1 LMNA 3185/4885MPO 3066/4885GLS 1455/4885
US-20200140429-A1 ANTI-HCMV COMPOSITIONS AND METHODS RPL35, RPL7, RPL5 LMNA 1720/4885MPO 2075/4885GLS 2041/4885
US-20220135556-A1 ANTI-HCMV COMPOSITIONS AND METHODS RPL35, RPL7, RPL5 LMNA 1720/4885MPO 2075/4885GLS 2041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.